Goldman Sachs Maintains Buy on Ascendis Pharma, Raises Price Target to $195
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Paul Choi maintains a Buy rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $170 to $195.
August 13, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Paul Choi maintains a Buy rating on Ascendis Pharma and raises the price target from $170 to $195.
The Buy rating and increased price target from a reputable analyst at Goldman Sachs is likely to positively influence investor sentiment and drive short-term price appreciation for Ascendis Pharma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100